共 8 条
[2]
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK ‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects[J] . H. Jenkins,Y. Sakurai,A. Nishimura,H. Okamoto,M. Hibberd,R. Jenkins,T. Yoneyama,K. Ashida,Y. Ogama,S. Warrington. Aliment Pharmacol Ther . 2015 (7)
[3]
The fight against gastric cancer – the IARC Working group report[J] . Dr. Rolando Herrero,Jin Young Park. Best Practice & Research Clinical Gastroenterology . 2014
[6]
High‐dose rabeprazole–amoxicillin versus rabeprazole–amoxicillin–metronidazole as second‐line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection[J] . H.Isomoto,K.Inoue,H.Furusu,A.Enjoji,C.Fujimoto,M.Yamakawa,Y.Hirakata,K.Omagari,Y.Mizuta,K.Murase,S.Shimada,I.Murata,S.Kohno. Alimentary Pharmacology & Therapeutics . 2003 (1)
[8]
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second‐line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance[J] . K.Murakami,R.Sato,T.Okimoto,M.Nasu,T.Fujioka,M.Kodama,J.Kagawa. Alimentary Pharmacology & Therapeutics . 2002 (1)